Skip to main content
PMC home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2009 Feb 3;23(1):39–46. doi: 10.1002/clc.4960230108

Lipid‐Altering Efficacy and Safety of Simvastatin 80 mg/Day: Long‐Term Experience in a Large Group of Patients with Hypercholesterolemia

Leiv Ose 1, Michael H Davidson 2, William Insull 2, Mei Wu 3, Ann C Tate 3, Michael R Melino 3, Michele Mercuri 3, Yale B Mitchel 3,✉, Evan A Stein 4, Johannes J P Kastelein 5, Russell S Scott 6, Donald B Hunninghake 7, Santiago Campodonico 8, Ivan D Escobar 9, Michael E Stepanavage 10, Helmut G Schrott 10
PMCID: PMC6654890  PMID: 10680028

Abstract

Background: Elevated levels of low‐density lipoprotein (LDL) cholesterol promote the development of atherosclerosis and coronary heart disease.

Hypothesis: Simvastatin 80 mg/day will be more effective than simvastatin 40 mg/day at reducing LDL cholesterol and will be well tolerated.

Methods: Two similar, randomized, multicenter, controlled, double‐blind, parallel‐group, 48‐week studies were performed to evaluate the long‐term lipid‐altering efficacy and safety of simvastatin 80 mg/day in patients with hypercholesterolemia. One study conducted in the US enrolled patients meeting the National Cholesterol Education Program (NCEP) LDL cholesterol criteria for pharmacologic treatment. In the other multinational study, patients with LDL cholesterol levels ≥4.2 mmol/l were enrolled. At 20 centers in the US and 19 countries world‐wide, 1,105 hypercholesterolemic patients, while on a lipid‐lowering diet, were randomly assigned at a ratio of 2:3 to receive simvastatin 40 mg (n = 436) or 80 mg (n = 669) once daily for 24 weeks. Those patients completing an initial 24‐week base study were enrolled in a 24‐week blinded extension. Patients who had started on the 80 mg dose in the base study continued on the same dose in the extension, while those who had started on the 40 mg dose were rerandomized at a 1:1 ratio to simvastatin 40 or 80 mg in the extension.

Results: There was a significant advantage in the LDL cholesterol‐lowering effect of the 80 mg dose compared with that of the 40 mg dose, which was maintained over the 48 weeks of treatment. The mean percentage reductions (95% confidence intervals) from baseline in LDL cholesterol for the 40 and 80 mg groups were 41% (42, 39) and 47% (48, 46), respectively, for the 24‐week base study, and 41% (43, 39) and 46% (47, 45), respectively, after 48 weeks of treatment (p < 0.001 between groups). Larger reductions in total cholesterol and triglycerides were also observed with the 80 mg dose compared with the 40 mg dose at Weeks 24 and 48. Both doses were well tolerated, with close to 95% of patients enrolled completing the entire 48 weeks of treatment. Myopathy (muscle symptoms plus creatine kinase increase > 10 fold upper limit of normal) and clinically significant hepatic transaminase increases (> 3 times the upper limit of normal) occurred infrequently with both doses. There was no significant difference between the groups in the number of patients with such increases, although there were more cases for both with the 80 mg dose.

Conclusions: Compared with the 40 mg dose, simvastatin 80 mg produced greater reductions in LDL cholesterol, total cholesterol, and triglycerides. Both doses were well tolerated.

Keywords: hypercholesterolemia, low‐density lipoprotein cholesterol, triglycerides, simvastatin.

Full Text

The Full Text of this article is available as a PDF (929.8 KB).

Reference

  • 1. Pedersen TR, Berg K, Cook TJ, Faergeman O, Haghfelt T, Kjekshus J, Miettinen T, Musliner TA, Olsson AG, Pyorala K, Thorgeirsson G, Tobert JA, Wedel H, Wilhelmsen L: Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1996; 156: 2085–2092 [PubMed] [Google Scholar]
  • 2. MAAS Investigators : Effect of simvastatin on coronary atheroma: The Multicentre Anti‐Atheroma Study (MAAS). Lancet 1994; 344: 633–638 [PubMed] [Google Scholar]
  • 3. Davidson MH, Stein EA, Dujovne CA, Hunninghake DB, Weiss SR, Knopp RH, Illingworth DR, Mitchel YB, Melino MR, Zupkis RV, Dobrinska MR, Amin RD, Tobert JA: The efficacy and six‐week tolerability of simvastatin 80 and 160 mg/day. Am J Cardiol 1997; 79: 38–42 [DOI] [PubMed] [Google Scholar]
  • 4. Stein EA, Davidson MH, Dobs AS, Schrott H, Dujovne CA, Bays H, Weiss SR, Melino MR, Stepanavage ME, Mitchel YB: Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients. Am J Cardiol 1998; 82: 311–316 [DOI] [PubMed] [Google Scholar]
  • 5. Ose L, Kastelein JJP, Scott R, Stein EA, Campodonico S, Escobar JD, Tate AC, Corsetti L, Shahane A, Mitchel YB, Mercuri M: Efficacy and six‐month safety of simvastatin 80 mg/day: Results from the Worldwide Simvastatin Expanded Dose Program (WSEDP). Nutr Metab Cardiovasc Dis 1998; 8: 143–151 [Google Scholar]
  • 6. Krauss RM, Deckelbaum RJ, Ernst N, Fisher E, Howard BV, Knopp RH, Kotchen T, Lichtenstein AH, McGill HC, Pearson TA, Prewitt TE, Stone NJ, Horn LV, Weinberg R: Dietary guidelines for healthy American adults. A statement for health professionals from the Nutrition Committee, American Heart Association. Circulation 1996; 94: 1795–1800 [DOI] [PubMed] [Google Scholar]
  • 7. Myers GL, Cooper GR, Winn CL, Smith SJ: The Centers for Disease Control‐National Heart, Lung, and Blood Institute Lipid Standardization Program: An approach to accurate and precise lipid measurements. Clin Lab Med 1989; 9 (1): 105–135 [PubMed] [Google Scholar]
  • 8. Steiner P, Freidel J, Bremner W, Stein E: Standardization of micromethods for plasma cholesterol, triglyceride and HDL‐cholesterol with the lipid clinics' methodology (abstr). J Clin Chem Clin Biochem 1981; 19: 850 [Google Scholar]
  • 9. Warnick G, Albers J: A comprehensive evaluation of the heparin manganese precipitation procedure for estimating high‐density lipoprotein cholesterol. J Lipid Res 1978; 19: 65–76 [PubMed] [Google Scholar]
  • 10. Program LRC: Manual of Laboratory Operations: Lipid and Lipoprotein Analysis. Washington, DC: US Dept. of Health Education and Welfare; NIH publication no. 361–132 1982; 678: 66–70 [Google Scholar]
  • 11. Stein E, Kreisberg R, Miller V, Mantell G, Washington L, Shapiro DR: Effects of simvastatin and cholestyramine in familial and non‐familial hypercholesterolemia. Multicenter Group I. Arch Intern Med 1990; 150: 341–345 [PubMed] [Google Scholar]
  • 12. Santer S, Santen R, Kulin H, Demers L: A model for validation of radioimmunoassay kit reagents: Measurement of follitropin and lutropin in blood and urine. Clin Chem 1981; 27: 1892–1895 [PubMed] [Google Scholar]
  • 13. Kubasik N, Hallaver G, Brodows R: Evaluation of direct solid phase radioimmunoassay for progesterone, useful for monitoring luteal function. Clin Chem 1984; 30: 284–286 [PubMed] [Google Scholar]
  • 14. Tdx System Operator's Manual, Abbot Diagnostics, Abbot Park, Ill, 1993. [Google Scholar]
  • 15. Newton WT, McGuigan JE, Jaffe BM: Radioimmunoassay of peptides lacking tyrosine. J Lab Clin Med 1970; 75: 886–892 [PubMed] [Google Scholar]
  • 16. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD: Cholesterol reduction yields clinical benefit: A new look at old data. Circulation 1995; 91: 2274–2282 [DOI] [PubMed] [Google Scholar]
  • 17. Pedersen TR, Olsson AG, Faergeman O, Kjekshus J, Wedel H, Berg K, Wilhelmsen L, Haghfelt T, Thorgeirsson G, Pyorala K, Miettinen T, Christophersen B, Tobert JA, Musliner TA, Cook TJ: Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 1998; 97: 1453–1460 [DOI] [PubMed] [Google Scholar]
  • 18. Stein EA, Lane M, Laskarzewski P: Comparison of statins in hypertriglyceridemia. Am J Cardiol 1998; 81: 66B–69B [DOI] [PubMed] [Google Scholar]
  • 19. Bakker Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacsohn JL, Weiss SR, Keilson LM, Brown WV, Miller VT, Shurzinske LJ, Black DM: Efficacy and safety of a new HMG‐CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. J Am Med Assoc 1996; 275: 128–133 [PubMed] [Google Scholar]
  • 20. Pedersen TR, Tobert JA: Benefits and risks of HMG‐CoA reductase inhibitors in the prevention of coronary heart disease: A reappraisal. Drug Safety 1996; 14: 11–24 [DOI] [PubMed] [Google Scholar]
  • 21. Shear CL, Franklin FA, Stinnett S, Hurley DP, Bradford RH, Chremos AN, Nash DT, Langendorfer A: Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. Effect of patient characteristics on lovastatin‐induced changes in plasma concentrations of lipids and lipoproteins. Circulation 1992; 85: 1293–1303 [DOI] [PubMed] [Google Scholar]
  • 22. Stein EA, Davidson MH, Dujovne CA, Hunninghake DB, Goldberg RB, Illingworth DR, Knopp RH, Miller VT, Frost P, Isaacsohn JL, Mitchel YB, Melino MR, Shapiro D, Tobert JA: Efficacy and tolerability of low‐dose simvastatin and niacin, alone and in combination, in patients with combined hyperlipidemia: A prospective trial. J Cardiovasc Pharmacol Ther 1996; 1: 107–116 [DOI] [PubMed] [Google Scholar]
  • 23. Bruckert E, De Gennes JL, Malbecq W, Baigts F: Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia. Clin Cardiol 1995; 18: 621–629 [DOI] [PubMed] [Google Scholar]
  • 24. Bradford RH, Shear CL, Chremos AN, Dujovne C, Downton M, Franklin FA, Gould AL, Hesney M, Higgins J, Hurley DP, Langendorfer A, Nash DT, Pool JL, Schnaper H: Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8,245 patients with moderate hypercholesterolemia. Arch Intern Med 1991; 151: 43–49 [DOI] [PubMed] [Google Scholar]
  • 25. Pharmaceuticals Parke‐Davis: Domestic Product circular: Lipitor tablets (atorvastatin calcium) (1997)
  • 26. Data on file at Merck.
  • 27. Pedersen T, Faergeman O: Simvastatin seems unlikely to cause impotence (letter). Br Med J 1999; 318: 192 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES